These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3764805)

  • 1. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect.
    Fernandez F; N'guyen P; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
    Thromb Res; 1986 Aug; 43(4):491-5. PubMed ID: 3764805
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin.
    Hoppensteadt D; Racanelli A; Walenga JM; Fareed J
    Semin Thromb Hemost; 1989 Oct; 15(4):378-85. PubMed ID: 2530633
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
    Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
    J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition by heparin of platelet accumulation in vivo.
    Barrett PA; Butler KD; Morley J; Page CP; Paul W; White AM
    Thromb Haemost; 1984 Jul; 51(3):366-70. PubMed ID: 6495256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The haemorrhagic and antithrombotic effects of dermatan sulphate.
    Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
    Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal and low molecular weight heparins: interaction with human platelets.
    Fabris F; Fussi F; Casonato A; Visentin L; Randi M; Smith MR; Girolami A
    Eur J Clin Invest; 1983 Apr; 13(2):135-9. PubMed ID: 6223824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets.
    Messmore HL; Griffin B; Fareed J; Coyne E; Seghatchian J
    Ann N Y Acad Sci; 1989; 556():217-32. PubMed ID: 2472085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease.
    Mikhailidis DP; Barradas MA; Jeremy JY; Gracey L; Wakeling A; Dandona P
    Eur J Clin Invest; 1985 Dec; 15(6):313-9. PubMed ID: 3938401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins.
    Messmore HL; Griffin B; Koza M; Seghatchian J; Fareed J; Coyne E
    Semin Thromb Hemost; 1991; 17 Suppl 1():57-9. PubMed ID: 1712512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
    Hoppensteadt D; Walenga JM; Fareed J
    Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin.
    Luzzatto G; Paolini R; Stevanato F; Simioni P; Cella G
    Angiology; 1989 Mar; 40(3):170-4. PubMed ID: 2916768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
    Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
    J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).
    Mikhailidis DP; Fonseca VA; Barradas MA; Jeremy JY; Dandona P
    Br J Clin Pharmacol; 1987 Oct; 24(4):415-24. PubMed ID: 3689624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oversulfated dermatan sulfate derivatives on platelet aggregation.
    Maaroufi RM; Giordano P; Triadou P; Tapon-Bretaudière J; Dautzenberg MD; Fischer AM
    Thromb Res; 2007; 120(4):615-21. PubMed ID: 17222891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets.
    Mastacchi R; Barbanti M; Bianchini P; Osima B
    Agents Actions; 1986 Mar; 17(5-6):512-4. PubMed ID: 3518359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collagen-induced platelet aggregation and release. II Critical size and structural requirements of collagen.
    Wang CL; Miyata T; Weksler B; Rubin AL; Stenzel KH
    Biochim Biophys Acta; 1978 Dec; 544(3):568-77. PubMed ID: 31930
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin.
    Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1991; 17 Suppl 1():60-4. PubMed ID: 2068572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.